Purulent acute otitis media

Summary

Purulent acute otitis media (MONDO:0001031) is a disease. A subtype of suppurative otitis media — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	purulent acute otitis media
Mondo ID	MONDO:0001031
DOID	DOID:10435
ICD-10-CM	H66.0
ICD-11	214476774
SNOMED CT	194281003
UMLS	C0271431
MedGen	543338
Is cancer (heuristic)	no

Also known as: acute suppurative otitis media · suppurative otitis media, acute

Disease family

This is a subtype of suppurative otitis media. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › auditory system disorder › middle ear disorder › otitis media › suppurative otitis media › purulent acute otitis media

Related subtypes (2): chronic purulent otitis media, chronic tubotympanic suppurative otitis media

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.